206 related articles for article (PubMed ID: 25134493)
1. Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.
Schopf L; Enlow E; Popov A; Bourassa J; Chen H
Ophthalmol Ther; 2014 Dec; 3(1-2):63-72. PubMed ID: 25134493
[TBL] [Abstract][Full Text] [Related]
2. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
[TBL] [Abstract][Full Text] [Related]
3. Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38.
Cavet ME; Glogowski S; Lowe ER; Phillips E
J Ocul Pharmacol Ther; 2019 Jun; 35(5):291-300. PubMed ID: 30907685
[No Abstract] [Full Text] [Related]
4. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.
Lyseng-Williamson KA
Drugs; 2013 Jun; 73(9):949-58. PubMed ID: 23740411
[TBL] [Abstract][Full Text] [Related]
5. Loteprednol etabonate: a formulation for short-term use in inflammatory flares in dry eye disease.
Paton DM
Drugs Today (Barc); 2022 Feb; 58(2):77-84. PubMed ID: 35188142
[TBL] [Abstract][Full Text] [Related]
6. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
Kang C; Keam SJ; Shirley M; Syed YY
Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521
[TBL] [Abstract][Full Text] [Related]
7. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
Sheppard JD; Comstock TL; Cavet ME
Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
[TBL] [Abstract][Full Text] [Related]
9. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
Abelson M; Howes J; George M
J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
[TBL] [Abstract][Full Text] [Related]
10. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.
Druzgala P; Wu WM; Bodor N
Curr Eye Res; 1991 Oct; 10(10):933-7. PubMed ID: 1959381
[TBL] [Abstract][Full Text] [Related]
11. Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop.
Coffey MJ; Decory HH; Lane SS
Clin Ophthalmol; 2013; 7():299-312. PubMed ID: 23430378
[TBL] [Abstract][Full Text] [Related]
12. The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares.
Gupta PK; Venkateswaran N
Ther Adv Ophthalmol; 2021; 13():25158414211012797. PubMed ID: 34017938
[TBL] [Abstract][Full Text] [Related]
13. Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease.
Venkateswaran N; Bian Y; Gupta PK
Clin Ophthalmol; 2022; 16():349-355. PubMed ID: 35173413
[TBL] [Abstract][Full Text] [Related]
14. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
Amon M; Busin M
Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
[TBL] [Abstract][Full Text] [Related]
15. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
Lane SS; Holland EJ
J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
[TBL] [Abstract][Full Text] [Related]
16. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.
Patel N; Nakrani H; Raval M; Sheth N
Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
Rajpal RK; Roel L; Siou-Mermet R; Erb T
J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
[TBL] [Abstract][Full Text] [Related]
18. Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate.
Soliman OAE; Mohamed EAM; El-Dahan MS; Khatera NAA
AAPS PharmSciTech; 2017 May; 18(4):1228-1241. PubMed ID: 27469220
[TBL] [Abstract][Full Text] [Related]
19. Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%).
Marlowe ZT; Davio SR
Clin Ophthalmol; 2014; 8():23-9. PubMed ID: 24357925
[TBL] [Abstract][Full Text] [Related]
20. Prolonged Release Niosomes For Ocular Delivery of Loteprednol: Ocular Distribution Assessment on Dry Eye Disease Induced Rabbit Model.
Ozdemir S; Uner B
AAPS PharmSciTech; 2024 May; 25(5):119. PubMed ID: 38816667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
